Peripheral Blood for Epidermal Growth Factor Receptor Mutation Detection in Non-Small Cell Lung Cancer Patients
Xuefei Li(Harbin Medical University), Caicun Zhou(Tongji University), Shengxiang Ren(Tongji University), Yishi Zhang(Children's Hospital of Chongqing Medical University), Chunxia Su(Tongji University), Ningning Cheng(Tongji University), Jiayu Li(Zhejiang Chinese Medical University), Chao Zhao(Tongji University), Xiaoxia Chen(Guangdong Academy of Medical Sciences), Weijing Cai(Hebei Medical University), Fei Zhou(Shanghai University), Mingchuan Zhao(Tongji University), Ruixin Ren(Tongji University)
Cited by 74
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
|Annals of Oncology|2015|467
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial
|Journal of Thoracic Oncology|2021|311
HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib
|Annals of Oncology|2018|217
Deep learning for autonomous ship-oriented small ship detection
|Safety Science|2020|207